Gene that inhibits tumor growth is shown to promote aggressive breast cancers

May 27, 2015, Agency for Science, Technology and Research (A*STAR), Singapore
Gene that inhibits tumor growth is shown to promote aggressive breast cancers
Expression of the gene RASAL2 can be used as a biomarker to distinguish between breast cancer patients with low (top) and high (bottom) expression levels and guide subsequent treatment. Credit: A*STAR Genome Institute of Singapore

A*STAR researchers have shown that the RASAL2 gene, which is known to inhibit tumor growth in some breast cancers, actually advances tumor formation and metastasis in more aggressive forms of breast cancer and have suggested its use as a diagnostic marker.

Breast cancer is often characterized by an overexpression of that bind hormones and trigger the disruption of cell division and DNA repair. Typically, cancer treatments that inhibit the activity of have a high rate of success, except in the case of (TNBC), which accounts for approximately 15 per cent of all cases. TNBC lose the ability to express hormone receptors, making the cancer more difficult to treat.

Qiang Yu's research at the A*STAR Genome Institute of Singapore focuses on finding the key molecules in a cancer cell's network responsible for making tumor cells more aggressive. "Identifying biomarkers which can define high-risk TNBC patients is one of our main interests," he says.

Leading a team of international scientists, Yu focused on the targets of small RNA molecules, or microRNAs, which often act as tumor suppressors and control the expression of genes that can promote cancer. If the levels of these microRNAs go down, the oncogenes' levels come up and tumors form. The researchers found reduced levels of a microRNA in TNBC and determined that its target was a gene called RASAL2.

Higher RASAL2 expression in TNBC correlates with a more aggressive tumor, a finding that intrigued Yu since it could not be easily explained by the gene's function. In tumors that express hormone receptors, the RASAL2 gene was shown to inhibit disease progression by inactivating Ras, one of the most common genes to contribute to human cancer.

Yu showed that the mechanism by which RASAL2 made TNBC cells more invasive does not require the inhibition of Ras. Instead RASAL2 binds a protein that inactivates Rac, another cancer-promoting protein, thus leading to higher Rac activity, which in turn makes tumor cells more prone to invading the surrounding tissue.

Yu does not see RASAL2 as a therapeutic target since its function might not be easily inhibited by a drug. "I think more likely RASAL2 can be pursued as a for aggressive TNBC," he says (see image).

Identifying the molecular signaling pathways in cancer cells and understanding how networks change and proteins take on opposite functions is critical for reliable diagnosis that will lead to effective therapy geared toward a patient's particular type of cancer.

Explore further: Scientists uncover gene associated with an aggressive breast cancer

More information: RASAL2 activates RAC1 to promote triple-negative breast cancer progression. The Journal of Clinical Investigation 124, 5291–5304 (2014). dx.doi.org/10.1172/JCI76711

Related Stories

Scientists uncover gene associated with an aggressive breast cancer

December 1, 2014
Scientists at A*STAR's Genome Institute of Singapore (GIS), in collaboration with local clinicians and colleagues in the USA, have identified a biomarker which is strongly associated with triple negative breast cancer (TNBC), ...

Protein linked to invasive spread of triple-negative breast cancer may lead to targeted therapies

February 26, 2014
Triple-negative breast cancer (TNBC) is one of the most aggressive forms of the disease and affects almost one in seven of the 1.5 million women diagnosed with breast cancer worldwide each year. TNBC tumors are missing three ...

Scientists discover new drug targets for aggressive breast cancer

July 26, 2013
Scientists at A*STAR's Genome Institute of Singapore (GIS) led in a study that has identified genes that are potential targets for therapeutic drugs against aggressive breast cancer. These findings were reported in the July ...

Discovery may help breast cancer treatment

November 7, 2014
Researchers led by Dr. Debra Auguste, associate professor, biomedical engineering, in the Grove School of Engineering at The City College of New York, have identified a molecule that could lead to developing treatment for ...

Prognostic role found for miR-21 expression in triple-negative breast cancer

December 2, 2014
"Triple-negative" breast cancer (TNBC) occurs in patients whose cells do not express receptors for estrogen, progesterone, and/or human epidermal growth factor receptor 2 (ER-/PR-/HER2-). Because of the absence of these predictive ...

Two new possible drug targets for triple negative breast cancer

May 27, 2014
The suppression of two genes reduce breast cancer tumor formation and metastasis by interfering with blood vessel formation and recruitment, report scientists from Houston Methodist and five other institutions in the Proceedings ...

Recommended for you

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Scientists block the siren call of two aggressive cancers

January 23, 2018
Aggressive cancers like glioblastoma and metastatic breast cancer have in common a siren call that beckons the bone marrow to send along whatever the tumors need to survive and thrive.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Workouts may boost life span after breast cancer

January 22, 2018
(HealthDay)—Longer survival after breast cancer may be as simple as staying fit, new research shows.

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.